MLL rearrangement
|
AML
|
MLL rearrangement
|
AML
|
SNDX-5613 Sensitive: B - Late Trials
|
SNDX-5613 Sensitive: B - Late Trials
|
MLL rearrangement
|
Leukemia
|
MLL rearrangement
|
Leukemia
|
SNDX-5613 Sensitive: C2 – Inclusion Criteria
|
SNDX-5613 Sensitive: C2 – Inclusion Criteria
|
MLL rearrangement
|
ALL
|
MLL rearrangement
|
ALL
|
CB-659 Sensitive: D – Preclinical
|
CB-659 Sensitive: D – Preclinical
|
MLL rearrangement
|
ALL
|
MLL rearrangement
|
ALL
|
irinotecan Sensitive: D – Preclinical
|
irinotecan Sensitive: D – Preclinical
|
MLL rearrangement
|
ALL
|
MLL rearrangement
|
ALL
|
doxorubicin hydrochloride + APH-0202 Sensitive: D – Preclinical
|
doxorubicin hydrochloride + APH-0202 Sensitive: D – Preclinical
|
MLL rearrangement
|
B Acute Lymphoblastic Leukemia
|
MLL rearrangement
|
B Acute Lymphoblastic Leukemia
|
OSE-127 Sensitive: D – Preclinical
|
OSE-127 Sensitive: D – Preclinical
|